首页> 外文期刊>Genetics and breeding >Stem cells and their significancefor the medical practice
【24h】

Stem cells and their significancefor the medical practice

机译:干细胞及其对医学实践的意义

获取原文
获取原文并翻译 | 示例
       

摘要

A review on the sources and the different methods forproducing stem cells was made. 'Also the limitations and perspectives fortherapeutic use of the human stem cells were considered. Embryonic stem(ES) cells derived from the inner cell masses (ICM) of blastocysts, fetalprimordial germ cells, stem cells from umbilical cord blood and from adulttissues are a valuable source of cells for regenerative therapy of damaged ordegenerating tissues and even of damaged organs. But there exist immuneresponses associated with the transplantation of the various stem cells, andthus lead to requirement for immunosuppressive drugs and/or immuno-modulatory protocols that carry the risk of serious and potentially life-threatening complications. Also, because of ethical considerations thepractical use of human ES cells produced from normal or nuclear tran-nsferred (NT) embryos is restricted. Three alternatives have been proposed:1) production of ES cells from preimplantation parthenogenetic or androge-netic embryos, homozygous for the genes of major histocompatibilitycomplex (MHC); 2) ES cells from preimplantation embryos produced bynuclear transfer from cells of adult humans in enucleated animal eggs; 3) EScells directly from adult somatic cells without NT. Even in these cases existspotential risk of incorrect expression of many genes, mainly imprinted genes,and this can lead to anomalies or even to cancer in the recipients. It isimportant, therefore, to continue research and to improve the understandingabout the molecular events that take place during nuclear reprogramming, inorder to develop potential new therapies. Especially useful can be the animalmodel systems connected with in vitro culture techniques.
机译:对来源和干细胞生产的不同方法进行了审查。 '还考虑了人类干细胞在治疗上的局限性和前景。胚泡干细胞,胎儿原始生殖细胞,脐带血干细胞和成年组织干细胞来源的胚胎干细胞是用于受损或退化组织甚至器官受损的再生治疗的重要细胞来源。但是存在与各种干细胞的移植相关的免疫反应,因此导致对免疫抑制药物和/或免疫调节方案的需求,这带来了严重且可能危及生命的并发症的风险。而且,出于伦理考虑,限制了从正常或核移植(NT)胚胎产生的人ES细胞的实际使用。提出了三种选择:1)从胚胎前的单性生殖或雄激素性胚胎产生ES细胞,这些胚胎与主要组织相容性复合体(MHC)的基因纯合。 2)通过去核动物卵中成年人类细胞的核转移产生的来自植入前胚胎的ES细胞; 3)ES细胞直接来自没有NT的成年体细胞。即使在这些情况下,也存在许多基因(主要是印迹基因)不正确表达的潜在风险,这可能会导致受体异常甚至癌症。因此,重要的是要继续研究并增进对核重编程过程中发生的分子事件的了解,以便开发潜在的新疗法。与体外培养技术有关的动物模型系统尤其有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号